Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch

Clinical and Translational Science

Volumn 10, Issue 2, 2017, Pages 84-92

  Scheerens, H ^a   Malong, A ^a   Bassett, K ^a   Boyd, Z ^a   Gupta, V ^a   Harris, J ^a   Mesick, C ^a   Simnett, S ^a   Stevens, H ^b   Gilbert, H ^a   Risser, P ^a   Kalamegham, R ^a   Jordan, J ^b   Engel, J ^b   Chen, S ^b   Essioux, L ^b   Williams, J A ^a  

^a GENENTECH INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ATEZOLIZUMAB; CETUXIMAB; CRIZOTINIB; DABRAFENIB; DEFERASIROX; ERLOTINIB; GEFITINIB; IMATINIB; NIVOLUMAB; OLAPARIB; OSIMERTINIB; PANITUMUMAB; PEMBROLIZUMAB; PERTUZUMAB; RUCAPARIB; TRAMETINIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VEMURAFENIB; VENETOCLAX; BIOLOGICAL MARKER;

ARTICLE; ASSAY; BLADDER CANCER; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COMPANION DIAGNOSTICS; COMPLEMENTARY DIAGNOSTICS; DIAGNOSIS; DIAGNOSTIC KIT; DIAGNOSTIC TEST; DRUG DEVELOPMENT; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIFE EXTENSION; MASTOCYTOSIS; MELANOMA; METASTATIC MELANOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NON SMALL CELL LUNG CANCER; OVARY CANCER; PATIENT CARE; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; THALASSEMIA; ALTERNATIVE MEDICINE; DIAGNOSTIC PROCEDURE; ECONOMICS; HEALTH CARE DELIVERY; LEGISLATION AND JURISPRUDENCE; MOLECULARLY TARGETED THERAPY; NEOPLASM; PERSONALIZED MEDICINE; PROCEDURES; REIMBURSEMENT; UNITED STATES;

BIOMARKERS; COMPLEMENTARY THERAPIES; DIAGNOSTIC TECHNIQUES AND PROCEDURES; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRECISION MEDICINE; QUALITY OF LIFE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85013805777     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12455     Document Type: Article

References (23)

1. FDA-NIH. Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. 2016.
2. Lotvall, J. et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J. Allergy Clin. Immunol. 127, 355–360 (2011).
3. Wenzel, S. Severe asthma: from characteristics to phenotypes to endotypes. Clin. Exp. Allergy 42, 650–658 (2012).
4. Hudis, C.A. Trastuzumab–mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39–51 (2007).
5. Rosenberg, J.E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016).
6. Agache, I. & Akdis, C.A. Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine. Allergol Int. 65, 243–252 (2016).
7. Cummings, C.A., Peters, E., Lacroix, L., Andre, F. & Lackner, M.R. The role of next-generation sequencing in enabling personalized oncology therapy. Clin. Transl. Sci. 9, 283–292 (2016).
8. HERCEPTIN(trastuzumab) [package insert] Genentech, Inc. 1998. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf
9. Milne, C.P., Bryan, C., Garafalo, S. & McKiernan, M. Complementary versus companion diagnostics: apples and oranges? Biomark Med. 9, 25–34 (2015).
10. Chapman, P.B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
11. Borghaei, H. et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 373, 1627–1639 (2015).
12. Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837–1846 (2016).
13. Milmo, S. Regulation of Medical Devices and Companion Diagnostics. Pharmaceutical Technology Europe [Internet]. 27, [6-8 pp.] (2015). Available from: http://www.pharmtech.com/regulation-medical-devices-and-companion-diagnostics.
14. Woodruff, P.G. et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am. J. Respir. Crit. Care Med. 180, 388–395 (2009).
15. Jia, G. et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J. Allergy Clin. Immunol. 130, 647–654 e10 (2012).
16. McKinney, E.F., Lee, J.C., Jayne, D.R., Lyons, P.A. & Smith, K.G. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523, 612–616 (2015).
17. Parkinson, D.R. et al. Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer. Clin. Cancer Res. 20, 1428–1444 (2014).
18. Russell, R. & Brightling, C.E. Anti-IL-5 for Severe Asthma: Aiming High to Achieve Success. Chest 150, 766–768 (2016).
19. Haldar, P. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360, 973–984 (2009).
20. Castro, M. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 3, 355–366 (2015).
21. Corren, J., Weinstein, S., Janka, L., Zangrilli, J. & Garin, M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest 150, 799–810 (2016).
22. Pavord, I.D. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380, 651–659 (2012).
23. FDA. Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product In: CDRH, CDER, CBER, editors. Maryland, 2016.